We compared the health-related quality of life (HRQOL) of disease-free lung cancer survivors with those from the general population. Background: Although clinical research usually is focused on how to better identify the lung patients most likely to benefit from surgery in terms of survival, few studies have concentrated specifically on HRQOL in diseasefree lung cancer survivors compared with that of the general population. Methods: We enrolled 830 disease-free cancer survivors (median time since diagnosis, 4.11 years) who had a past diagnosis of lung cancer and treated with curative surgery (stage from 0 to III) at either of 2 hospitals between 2001 and 2006, and 1000 subjects without a history of cancer were selected randomly from a representative sample of general Korean population. Subjects filled out a questionnaire that included the European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30 and the lung cancer module. Results: There were no clinically meaningful differences between the diseasefree lung cancer survivors and general population in terms of any of the functioning subscales and most of the symptoms. However, survivors exhibited clinically meaningful worse dyspnea and financial problems on the EORTC QLQ-C30 subscales and dyspnea, coughing, and pain in chest wall on the EORTC QLQ-LC13 subscales than the general population. There was no clinically significant difference between the survivor groups according to the survival time. Survivors receiving lung resection, radiotherapy, and chemotherapy had clinically meaningful worse dyspnea than survivors receiving only lung resection. Lung cancer survivors with a respiratory or cardiologic comorbidity showed clinically meaningful worse social functioning, fatigue, dyspnea, and financial problems. Conclusions: These findings afford useful information clinicians preparing patients for lung cancer treatment by providing them with an understanding of the potential outcomes, and also for potential intervention targeting supportive care needs. (Ann Surg 2012;255:1000-1007 A lthough lung cancer has one of the worst prognoses, 1 the practice of low-dose computed tomographic scanning as an early detection tool and improvement in patient management has increased the number of long-term lung cancer survivors.
in 2009 was 16.7%. 6 Surgical resection is considered to offer the best survival outcomes for early-stage non-small-cell lung cancer. 7 Although clinical research is usually focused on how to better identify the patients most likely to benefit from surgery in terms of survival, patients and surgeons also need information about the potential health-related quality of life (HRQOL) outcomes. [8] [9] [10] Selfreported multidimensional HRQOL data describing physical, psychological, social, and existential well-being after the diagnosis of cancer have been accumulating. 11 However, most of the literature focuses on short-term HRQOL outcomes 8, 9, 12 or on patients with advanced-stage disease 11, [13] [14] [15] because of the poor prognosis. 15 A comparison with population-based reference data can provide greater insight into the altered HRQOL of cancer patients [16] [17] [18] [19] and enable health care providers to set HRQOL target levels 11 and allow a precise estimation of the risk in tailored intervention strategies. 2 We compared the HRQOL of disease-free lung cancer survivors with those from the general population and evaluate the impact of types of treatment, period after treatment, and comorbidity on survivors' HRQOL. We hypothesized that HRQOL would be poorer in lung cancer survivors than in the general population.
MATERIALS AND METHODS

Participants and Procedures
To understand lung cancer survivorship, a study was designed to identify important survivorship issues including HRQOL, health behavior, screening of a second primary cancer, and rehabilitation.
Lung Cancer Survivors
We identified 2049 patients who had been treated for lung cancer in 2 hospitals, the Samsung Medical Center (SMC) and National Cancer Center (NCC) in South Korea, from 2001 through 2006. We collected information about the primary cancer site, date of diagnosis, stage, type of treatment, and other clinical characteristics from the hospital cancer registries. Patients were eligible to participate if they (1) had a past diagnosis of lung cancer, (2) were treated with curative surgery, and (3) had no other history of cancer. Eligible subjects were contacted by telephone, and those who agreed to participate were surveyed by an interviewer with questionnaires at home or the clinic. We excluded from this analysis the subjects whose cancer had recurred at that time. Because video-assisted thoracic surgery (VATS) was not often performed from 2001 through 2006, we also excluded patients who received it. Thus, all patients in this study had undergone pulmonary resection via open thoracotomy. All participants provided written informed consent. the size of individual groups and corrects for differences in the probability of larger and smaller groups being sampled. All participants provided written informed consent. The control group population and data collection methods have previously been described elsewhere. 21 The institutional review board of the NCC and the SMC reviewed and approved the protocol of our study.
Instruments
Patients completed a questionnaire that covered demographic and clinical characteristics, and a number of standardized instruments designed to assess the HRQOL, existential well-being, fatigue, and depression. We constructed 1 questionnaire to examine HRQOL for lung cancer survivors. Questions covered the following topics: the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core-30 item (EORTC QLQ-C30) and lung cancer module (QLQ-LC13).
The EORTC QLQ-C30 is a 30-item cancer-specific questionnaire for assessing the general HRQOL of cancer patients. 22 The questionnaire incorporates 5 functioning domains (physical, role, cognitive, emotional, and social), 3 symptom scales (fatigue, pain, and nausea and vomiting), global health and overall HRQOL scales, and several single items that assess additional symptoms commonly reported by cancer patients (eg, dyspnea, appetite loss, sleep disturbance, constipation, and diarrhea) along with the perceived financial impact of disease and treatment. The QLQ-LC13 was designed to assess the impact of common lung cancer treatment modalities. The QLQ-LC13 has 1 multi-item scale (dyspnea) and 9 single items (pain in the arm/shoulder, chest, and other organs; cough; hemoptysis; dysphagia; peripheral neuropathy; alopecia; and mouth sores). The Korean version of QLQ-C30 was validated, and the QLQ-LC13 was translated into Korean by the forward-backward translation process and was pilot-tested with the original author's approval.
In addition to the previously described measures, the full survey instrument also included items concerning the utilization of cancer information and complementary and alternative medicine needs after treatment, health behavior, and screening for a second primary cancer, return to work, posttraumatic growth, fatigue, distress, and sexuality. We will publish these findings in the future. The feasibility and comprehensibility of the survey instrument were pretested with 20 lung cancer survivors. Completing the entire questionnaire took approximately 50 minutes.
Statistical Methods
Propensity-Based Weighting, Propensity Adjustment
We performed all analyses using data weighted to the population of eligible patients because half of the patients did not respond, and those who did respond might have differed significantly from those who did not, causing a selection bias. To adjust for observed differences between survey participants and nonparticipants, we used a weighting method based on propensity scores. 23 Propensity scores were defined as the conditional probability of being a respondent given all covariates available from both responding and nonresponding survivors (age, gender, region, hospital, survival times, and type of treatment), which we collected from hospital cancer registries. After propensity scores were assigned, subjects were grouped into quintiles and given the weight, which was the inverse of the mean propensity score for the stratum. In addition to propensitybased weights, we used 2 different propensity scores to control for differences in the characteristics: (1) between survey participants and nonparticipants in the lung cancer patients (age, gender, region, hospital, survival times, and type of treatment) and (2) between lung cancer patients and the general population group (age, gender, region, marital status, education, house income, occupational status, BMI [body mass index], alcohol use, smoking status, and comorbidity). 
Analysis of Outcomes
We scored the QLQ-C30 and QLQ-LC13 items according to the EORTC scoring manual. We linearly transformed the QLQ-C30 and QLQ-LC13 data to yield scores from 0 to 100; a higher score represented a better level of functioning or a higher level of symptoms respectively. We handled incomplete questionnaires according to the developers' recommendations.
We used descriptive statistics for clinical, socioeconomic, and therapeutic variables and t and χ 2 tests. We compared lung cancer survivors with the general population controls on the basis of multivariate (age, marital status, education, religion, and employment status)-adjusted HRQOL means and the proportion of "problematic groups" in each HRQOL scale. We defined a problematic group as one with a global HRQOL or functioning scale score of 33 or less, or a symptom scale score of 66 or more, on the QLQ-C30 and QLQ-LC13, respectively. 24 We also compared multivariate-adjusted means (age, sex, type of treatment, time since surgery, and comorbidity) of HRQOL between the treatment subgroups. We used analysis of covariance with a generalized linear model to determine significant differences between groups. We used multiple regression analysis to examine the impact of demographic and clinical characteristics on HRQOL. Because there were multiple comparisons, we considered a P value less than 0.01 to be statistically significant on the univariate and multivariate analyses, and we defined a "clinically meaningful" difference in HRQOL as a 10-point difference in the mean score. 22, 24 All statistical tests were 2-sided. All statistical tests were 2-sided and performed using SAS version 9.2 (SAS Institute, Inc, Cary, NC).
RESULTS
Subjects and Recruitment Results
We identified 2049 potentially eligible lung cancer survivors from the participating registries. Of these, 126 (6.1%) had died. We made multiple attempts to contact the others by postcard or telephone but were not able to reach 290 (14.2%) of them; the most frequent reason for contact failure was a change of address or telephone number. Of the 1633 (79.7%) patients who were contacted, 727 (35.5%) refused to participate. The reasons given most frequently were that the survey was inconvenient, that it took too long to complete, or that the patient felt too ill. Ultimately, 906 (44.2%) patients consented to participate to the survey. Of these, we excluded 76 patients who had Copyright © 2012 Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited. recurrent cancer at the time, 830 patients remained in the study and 803 patients did not participate in survey (Fig. 1) .
About the control group, 1483 refused to participate or did not complete the survey among 2483 eligible persons; 1000 did complete the survey, yielding a response rate of 40.3%. The most frequent reasons people gave for refusing to participate were that they felt too busy to complete the questionnaire (n = 670), that the survey was inconvenient (n = 332), and that they did not want to provide personal information (n = 165).
Sociodemographic and Clinical Characteristics
Compared with patients who did not respond to the questionnaire, responders who lived in metropolitan areas had shorter survival times and received combined treatment with chemotherapy and/or radiation therapy along with the operation (P < 0.01). After adjustment for the propensity score, however, no significant differences were evident between them ( Table 1) .
The lung cancer group differed significantly from the general population control group in several sociodemographic and healthrelated characteristics. After adjustment for the propensity score, however, no significant differences were evident ( Table 2) . Figure 2 presents a comparison of least mean square score (adjusted for age, sex, and comorbidity) of subscales of the EORTC QLQ-C30 and QLQ-LC13 between the lung cancer survivors and general population groups. Lung cancer survivors and general population subjects did not exhibit significantly different multivariateadjusted mean scores and clinically meaningful worse scores as 10-point than the general population in most of the functioning and symptoms except for dyspnea and financial problems on the subscales of the EORTC QLQ-C30 and dyspnea, coughing, and pain in chest wall on subscales of the EORTC QLQ-LC13.
Comparison of HRQOL Between Lung Cancer Survivors and the General Population
HRQOL by Survival Times After Diagnosis in Lung Cancer Survivors
Most of the HRQOL scores based on survival time did not significantly differ in the function or symptom subscales of EORTC QLQ-C30 or QLQ-LC13 except for pain and especially chest pain. Moreover, there was no clinically significant difference between groups in terms of survival time (Table 3) .
HRQOL by Types of Treatment in Lung Cancer Survivors
Most HRQOL scores by treatment type did not significantly differ in any of the functioning or symptom subscales of EORTC QLQ-C30 or QLQ-LC13, except for physical, role and social functioning, financial problems, and dyspnea. Compared with survivors receiving only lung resection, survivors receiving both lung resection and radiotherapy were clinically meaningfully worse and had worse financial problems. Cancer survivors receiving lung resection, radiotherapy, and chemotherapy showed clinically meaningful worse score in terms of dyspnea than survivors receiving only lung resection (Table 4) . 
Influence of Comorbidities on Survivor QOL
When compared by least mean square analysis of covariance, the lung cancer survivors with comorbidities reported significantly lower functioning and higher level of symptoms than survivors without any comorbidity except for nausea/vomiting, insomnia, appetite loss, constipation, and diarrhea on the EORTC QLQ-C30 symptom subscales and hemoptysis, sore mouth, dysphagia, and pain in chest on the EORTC QLQ-L13 subscales. When a clinically meaningful difference was defined as more than 10 points, however, cancer survivors with a respiratory or cardiologic comorbidity had a clinically lower level of social functioning, along with clinically higher level of symptoms such as fatigue, dyspnea, and financial problems on the EORTC QLQ-C30 subscales (Table 5) .
DISCUSSION
To our knowledge, this is the first large study to compare the HRQOL of lung cancer survivors with the general population. As demonstrated by these findings, lung cancer survivors have not only the general problems of cancer survivors but also certain specific problems with different HRQOL and potentially different rehabilitation needs. 11 The findings show that lung cancer HRQOL is comparable to the HRQOL (ie, clinically not different) on all of the HRQOL subscales except a few. We found that, compared with general population, lung cancer survivors had no clinically meaningful difference across all dimensions of functioning compared to the general population. Earlier studies report that HRQOL is impaired by lung cancer surgery but quickly returns to preoperative level within 6 to 12 months 8,9,25-28 and 2 years after surgery displays little difference. 8, 11 Our results provide additional support for the recovery of well-being. However, we found that, compared with general population, cancer survivors had more severe respiratory problems such as dyspnea, chest pain, cough and financial problems even after recovery from treatment. The findings that lung cancer survivors, compared with the general population, had clinically meaningful differences in subscale scores for financial problems, cough, dyspnea, and chronic chest pain have important implications for planning for their care. Financial difficulties have also been reported in stomach cancer survivors, 29 and lung cancer survivors have more difficulty working and report more disruptions in day-to-day activity than survivors of other cancers, 30 which might lead to reduced income and financial difficulties. Common complaints of thoracotomy patients are respiratory symptoms with dyspnea and cough 15 and the chronic pain seen after lung cancer treatment, 2, 8 a pain that persists in about 1 of 3 lung cancer survivors. 2, 31, 32 The survivors' perception of pain and dyspnea was important to the perceived HRQOL, implying a need for monitoring respiratory symptoms and chronic pain. 2, 8 In this study, however, we found only small and not clinically meaningful differences in those symptoms between short-and long-term survivors. Those problems, though, can provide useful information for clinicians as they prepare patients for lung cancer surgery in the areas of informed decision-making, planning, and referral to the appropriate services, all of which require a full understanding of the impairment and its difficulties. Our study suggested that while the combination of chemotherapy and radiotherapy after thoracotomy did not show clinically meaningful differences in many symptoms of EORTC QLQ-C30 and its lung cancer module, it might result in clinically meaningful changes in dyspnea symptoms. Following lung resection, dyspnea is a common sequela of radiation therapy and many chemotherapeutic agents. 2, [33] [34] [35] The recent wider application of multimodality treatment options thus may influence the clinical significance of dyspnea.
In this study, more than half of the survivors had at least 1 comorbid condition, which is comparable with earlier findings. 11 The presence of cardiac or pulmonary disease was clinically negatively related to HRQOL in terms of social functioning and symptoms (fatigue, dyspnea, and financial difficulties). In particular, the comorbid condition of cardiac disease might have a significant negative impact on the HRQOL outcomes in cancer survivors. 2, [36] [37] [38] The interesting findings from this study suggest that after the initial diagnosis, and tailored interventions together with risk assessment such as multimodality treatment, continued smoking, and comorbidities should be provided for respiratory symptoms, pain, financial problems. 8, 11, 39 In addition, long-term intervention strategies for ameliorating respiratory symptoms and easing socioeconomic difficulties, and continued surveillance of lung cancer survivors with recurrence, need to be included in survivorship care planning. 2 There are important limitations to consider in interpreting the results of this study. One of the threats to validity is the low response rate (44.2%), which restricted the generalizability of our findings to similar groups of lung cancer survivors. More severely impaired survivors may have elected not to participate. However, we minimized that potential bias by using a response propensity-weighted analysis. Second, another limitation was selection bias, which restricted the generalizability of these findings to similar groups of lung cancer survivors. Our study sample may not be representative of the general population of lung cancer survivors, because it was accrued from 2 selected academic centers. Third, because we did not match treatment and control subjects by age and sociodemographic characteristics, there may have been a selection bias. However, the propensity-based weighting method allows for much better control than prior studies of cancer survivors who were matched on only a few characteristics, such as age and education. 40 In addition to the biases we adjusted for, there might also be a bias following from the lung cancer survivors' being older than the general population and having had chemo-/radiation therapy, which the adjustment for propensity scores would not have overcome. Fourth, in this cross-sectional study, we were not able to assess HRQOL changes before and after treatment, thus it was not possible to determine how the HRQOL before lung cancer treatment influenced the HRQOL after treatment. Fifth, though it would be reasonable to compare the lung cancer patients' HRQOL with the HRQOL of the patients who underwent a thoracotomy for other purposes, this study did not include them. For greater understanding of lung cancer patients' HRQOL, further studies need to be done with those patients included.
In spite of its limitations, this study did indicate that diseasefree survivors of lung cancer had good HRQOL, but many lung cancer survivors had cough, dyspnea, and pain, as well as associated financial problems, compared with the general population. These findings comprise useful information for clinicians preparing patients for lung cancer treatment by providing them with an understanding of the potential outcomes (HRQOL). 8 They also can serve as the basis for potential intervention for rehabilitation and supportive care needs among lung cancer survivors after cancer treatment. 11 Further study is needed to explore potential interventions to support lung cancer patients afflicted with pulmonary symptoms, pain, and other cardiopulmonary diseases.
